Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P170030/S052

Orsiro Mission Sirolimus Eluting Coronary Stent System

Biotronik AG · Decision date Jun 5, 2026

FDA DECISIONP170030/S052

What did the FDA approve?

FDA records P170030/S052 as a supplement to PMA P170030, with the supplement type “135 Review Track For 30-Day Notice”. The recorded decision is approval, dated Jun 5, 2026.

FDA approval order statement

the introduction of a new production site for supply of the hypotube and a new hypotube extrusion process
Regulatory pathway
PMA supplement
Supplement type
135 Review Track For 30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Jun 5, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P170030/S052
Regulatory pathway
PMA supplement
Applicant
Biotronik AG
Product code
NIQ
Decision code
APPR
Decision date
Jun 5, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Coronary drug-eluting stent.

Applicant
Biotronik AG
Product code
NIQ
FDA device class
3

For the original device and its historical approval scope, see PMA P170030. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P170030 · Original PMA

    ORSIRO Sirolimus Eluting Coronary Stent System

  2. P170030/S052 received

    Application receipt date recorded by FDA.

  3. P170030/S055 · Related supplement

    Orsiro Mission Sirolimus Eluting Coronary Stent System; Synsiro Pro Sirolimus Eluting Coronary Stent System

  4. P170030/S056 · Related supplement

    Orsiro Mission Sirolimus Eluting Coronary Stent System

  5. P170030/S059 · Related supplement

    Orsiro Mission Sirolimus Eluting Coronary Stent System, Synsiro Pro Sirolimus Eluting Coronary Stent System

  6. P170030/S060 · Related supplement

    Orsiro Mission Sirolimus Eluting Coronary Stent System; Synsiro Pro Sirolimus Eluting Coronary Stent System

  7. P170030/S061 · Related supplement

    ORSIRO Sirolimus Eluting Coronary Stent System; Synsiro Pro Sirolimus Eluting Coronary Stent System

  8. P170030/S047 · Related supplement

    Orsiro Mission Sirolimus Eluting Coronary Stent System

  9. P170030/S062 · Related supplement

    ORSIRO Sirolimus Eluting Coronary Stent System

  10. P170030/S052 · FDA decision

    135 Review Track For 30-Day Notice

  11. P170030/S058 · Related supplement

    Orsiro Mission Sirolimus Eluting Coronary Stent System

  12. P170030/S064 · Related supplement

    Orsiro Mission larger diameter stents Ø 4.5 5.0 mm

  13. P170030/S065 · Related supplement

    ORSIRO Sirolimus Eluting Coronary Stent System

  14. P170030/S066 · Related supplement

    ORSIRO Sirolimus Eluting Coronary Stent System

Timeline entries are records held by MedtechLedger for P170030. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P170030

Product / regulatory recordCompanyPathwayDecision dateSource
Biotronik AGPMA approvalFeb 22, 2019FDA
Biotronik AGPMA supplementAug 19, 2025FDA
Biotronik AGPMA supplementOct 10, 2025FDA
Biotronik AGPMA supplementFeb 20, 2026FDA
Biotronik AGPMA supplementFeb 22, 2026FDA
Biotronik AGPMA supplementApr 1, 2026FDA
Biotronik AGPMA supplementApr 15, 2026FDA
Biotronik AGPMA supplementApr 15, 2026FDA
Biotronik AGPMA supplementJun 11, 2026FDA
Biotronik AGPMA supplementJul 23, 2026FDA
Biotronik AGPMA supplementAug 7, 2026FDA
Biotronik AGPMA supplementSep 24, 2026FDA

Explore the linked device profile

Other records with product code NIQ

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biotronik AG

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Ackerstrasse 6, Bülach, 8180

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records